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Identification of Novel Pharmacological Activities of
an Antifungal Agent, Nystatin, to Promote Dendritic
Cell Maturation
Yasushi Ogawa1,2, Norikatsu Mizumoto1,2, Hiroaki Tanaka1, Hironori Matsushima1 and Akira Takashima1
As an unbiased functional screen to identify agents activating dendritic cells (DCs), we recently developed a
DC-based biosensor system, in which a stable murine DC line XS106 was engineered to express the yellow
fluorescent protein (YFP) gene under the control of the IL-1b promoter. Here we report that nystatin (NYT), an
antifungal drug of the family of polyene macrolide antibiotics, elevated YFP expression by the resulting XS106-
pIL1-YFP DC biosensor clone in a dose-dependent fashion. With respect to the underlying mechanisms, NYT
activated the NFkB p65 and c-Rel subunits in the parental XS106 DC line. Moreover, NYT dose-dependently
increased the surface expression of major histocompatibility complex (MHC) class II (MHC II), CD40, CD54,
CD80, and CD86 by murine bone marrow-derived DCs and triggered their robust production of IL-1b, IL-6, IL-12,
tumor necrosis factor a, and macrophage inflammatory protein-1a. Our results document previously
unrecognized pharmacological activities of the most commonly used antifungal drug to promote DC
maturation.
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INTRODUCTION
Dendritic cells (DCs) in the peripheral epithelial tissues, for
example, Langerhans cells (LCs) in the epidermis, are
considered as ‘‘immature’’ antigen-presenting cells specia-
lized for at least two important tasks. First, they constantly
incorporate surrounding materials (including antigens) via
endocytosis, macropinocytosis, and phagocytosis. Secondly,
they function as biosensors by detecting microbial products,
inflammatory mediators, and danger signals that emerge in
the epithelial tissue microenvironment (Romani et al., 2003;
Larrengina and Falo, 2005). Upon sensing such signals,
immature DCs differentiate into fully potent antigen-present-
ing cells capable of activating immunologically naive T cells
efficiently. This process, known as DC maturation, is
accompanied by rapid and coordinated reprogramming of
gene expression, surface phenotype, and function. For
example, DCs begin to elevate the surface expression of
MHC II and costimulatory molecules, to release several
cytokines and chemokines, and to migrate from peripheral
tissues to the lymph nodes, where antigen presentation takes
place. Thus, DC maturation is the initial and key event in
the initiation of innate and adaptive immune responses
(Banchereau and Steinman, 1998).
We have recently developed a highly sensitive, unbiased
functional screen to detect DC-stimulatory signals (Mizumoto
et al., 2005a). Briefly, the XS106 DC line derived from the
epidermis of murine skin was transduced to express the
yellow fluorescent protein (YFP ) gene under the control of
murine IL-1b promoter. Consistent with our previous finding
that the parental XS106 DC line secreted IL-1b protein in
response to many different biological and pharmacological
stimuli (Mizumoto et al., 2005b), the resulting XS106-pIL1-
YFP DC biosensor clone responded to the same stimuli by
elevating YFP expression (Mizumoto et al., 2005a). By testing
a small chemical library obtained from the Developmental
Therapeutic Program at the National Cancer Institute and a
second library of 880 drugs approved by Food and Drug
Administration, we identified several compounds that sig-
nificantly elevated YFP expression by the DC biosensor
clone. These compounds included chemotherapeutics of the
camptothecin family of topoisomerase I inhibitors and two
microtubule depolymerizing drugs, colchicine and podo-
phyllotoxin. Although camptothecin derivatives induced only
phenotypic maturation of bone marrow-derived DCs (BM-
DCs), colchicine and podophyllotoxin both elicited full
maturation characterized by elevated expression of MHC II
and costimulatory molecules, production of several cytokines
and chemokines, and augmented capacity to activate
immunologically naive T cells (Mizumoto et al., 2005a).
Here we report potent DC-stimulatory potentials of a
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commonly used antifungal drug identified by DC biosensor
screening and its pharmacological activities to promote
phenotypic and functional maturation of DCs in vitro.
RESULTS AND DISCUSSION
Identification of DC-stimulatory potentials of nystatin
We screened the Food and Drug Administration-approved
drug library by adding individual test compounds at 4 mg/ml
to microcultures of the XS106-pIL1-YFP DC biosensor clone.
After 16 hours incubation, we examined YFP expression by
the DC clone by semiautomated flow-cytometric analysis, in
which the extent of YFP signals was assessed based on the
mean fluorescence intensity. The compounds elevating the
mean fluorescence intensity values above the baseline level
(the meanþ 3 standard deviation (SD) observed in the control
microcultures) were then scored as ‘‘hits’’. Of several newly
identified hit compounds, we chose to focus our present
effort on nystatin (NYT), because this polyene macrolide
antibiotic is the most frequently used topical antifungal agent
for the treatment of mucocutaneous candidiasis and other
superficial fungal infections (Kobayashi and Medoff, 1977;
Bolard, 1986). As shown in Figure 1a (closed circles), NYT
was found to elevate YFP expression by the DC biosensor
clone in a dose-dependent manner, with significant (Po0.05)
changes detectable in a range from 0.5 to 4 mg/ml.
Importantly, the cell viability measured concurrently by
propidium iodide (PI) uptake remained unaffected by NYT
at any tested concentration (open circles). These observations
revealed a potent pharmacological activity of NYT to induce
IL-1b promoter activation in the DC biosensor clone at
noncytotoxic concentrations.
To characterize the underlying mechanisms, we next
measured NFkB activation in the parental XS106 DC line
after exposure to 4 mg/ml NYT. In agreement with our
previous finding that XS106 DCs exhibit relatively high
steady-state NFkB activities in the absence of exogenous
stimuli (Mizumoto et al., 2005b), all four NFkB subunits
(p50, p65, c-Rel, and RelB) were detectable in the nuclear
extracts isolated from XS106 DCs treated with vehicle alone
(Figure 1b). Importantly, NYT treatment induced significant
(Po0.001) increases in the nuclear contents of p65 and
c-Rel subunits. Not only do these observations duplicate
the NFkB activation profiles we observed in XS106 DCs
after treatment with topoisomerase I inhibitors or micro-
tubule depolymerizing agents (Mizumoto et al., 2005a),
they also corroborate the current concept that NFkB
activation represents an initial and indispensable event in
the DC maturation process (Giannoukakis et al., 2000;
Yoshimura et al., 2001).
Pharmacological effects of NYT on DCs
A key question concerns whether NYT is capable of
activating bona fide DC populations. To test this, we next
examined the potential of NYT to induce phenotypic
maturation of murine BM-DCs. Following 20 hours incuba-
tion with vehicle alone or NYT at different doses, BM-DC
preparations were tested for surface expression of MHC II,
CD40, CD54, CD80, and CD86 within the CD11cþ
populations. NYT treatment elevated the expression of these
phenotypic markers of DC maturation in a dose-dependent
fashion. Significant (Po0.05) upregulation of all five markers
was achieved at 2 mg/ml (Figure 2a). It should be noted that
NYT showed no significant cytotoxicity against BM-DCs even
at the highest tested concentration (4 mg/ml).
Some of the agents causing phenotypic maturation of DCs
are known to trigger cytokine production only in modest
magnitudes or in Th2-skewed profiles (Pulendran, 2005). In
fact, microtubule depolymerizing drugs, but not topo-
isomerase I inhibitors, induced marked cytokine production
by BM-DCs (Mizumoto et al., 2005a). Importantly, NYT
treatment dose-dependently augmented the production of IL-
1b, IL-6, IL-12, tumor necrosis factor a, and macrophage
inflammatory protein-1a by BM-DCs. Significant (Po0.01)
increases of all five factors were induced at 2 mg/ml and their
maximal production was observed at 4 mg/ml (Figure 2b).
A functional hallmark of DC maturation is the acquisition
of an elevated capacity to activate naive T cells. Following
















































Figure 1. DC-stimulatory potentials of NYT. (a) The XS106-pIL1-YFP DCs
were incubated for 16 hours with NYT at the indicated concentrations and
then examined for YFP expression (K) and cell viability (J). The data are
representative of four independent experiments showing mean fluorescence
intensity values for YFP signals and the percentages of PI-negative cells
(mean7SD, n¼3). (b) The parental XS106 DC line was incubated with
4mg/ml NYT or vehicle alone for 6 hours and then examined for the activation
profiles of the indicated NFkB subunits, using an enzyme-linked immuno-
sorbent assay-based assay. The data are representative of two independent
experiments showing the OD450 values (mean7SD, n¼3). In both panels,
statistically significant differences compared with the control treated with
vehicle alone are indicated with asterisks (*Po0.05, **Po0.01, and
***Po0.001).
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20 hours incubation with NYT, BM-DCs were washed
extensively and then tested for their capacity to stimulate
allogeneic T cells in mixed leukocyte reactions. In some
experiments, NYT pretreatment produced significant
(Po0.05), albeit modest, augmentation of the T-cell-stimula-
tory capacity compared to vehicle pretreatment (Figure 3a). It
should be emphasized, however, that such ‘‘positive’’ results
were observed only in four out of 10 independent experi-
ments. In other six experiments, NYT treatment failed to
induce statistically significant enhancement (Figure 3b). This
failure was not due to accelerated DC death because the
viability of CD11cþ populations in allo-mixed leukocyte
reaction microcultures was not reduced by NYT treatment
(89.670.4%, n¼3) compared to vehicle treatment
(87.971.0%). The presence of NYT-pretreated DCs did not
inhibit rapid T-cell proliferation induced by phorbol myristate
acetate and ionomycin, suggesting it unlikely that small
amounts of NYT potentially carried over by DCs might
directly impair T-cell mitosis (Figure 3c). Thus, we have
interpreted our results to suggest that NYT delivers DC
activation signals leading to full phenotypic maturation and
robust cytokine production, but not to optimal augmentation
of T-cell-stimulatory activities.
Concluding remarks
This study is not the first reporting immunostimulatory
potentials of NYT. For example, NYT has been shown to
induce nonspecific mitosis and polyclonal antibody produc-
tion by B cells (Ishikawa et al., 1977), to promote
prostaglandin synthesis by monocytes (Wiegand et al.,
1988), and to elicit a tumoricidal activity by macrophages
(Klein et al., 1980). Our findings now document novel
pharmacological activities of NYT to induce phenotypic
maturation and cytokine/chemokine production by DCs.
The antifungal activity of NYT is generally attributed to
increased membrane permeability through formation of
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Figure 2. Capacity of NYT to induce phenotypic maturation and cytokine
production by BM-DCs. (a) BM-DCs (1106 cells/ml) were cultured for
20 hours with NYT at the indicated concentrations and then examined for
surface phenotype and cell viability. The data show the mean fluorescence
intensity values for the indicated surface molecules and the percentages of
PI-negative cells within the CD11cþ DC populations (mean7SD, n¼ 3).
Two sets of cell viability data are shown for their corresponding surface
phenotype data in different symbols. (b) Culture supernatants collected from
the above BM-DC cultures were examined by enzyme-linked immunosorbent
assay for the indicated soluble factors (mean7SD, n¼ 3). In both panels, the
data are representative of at least two independent experiments, and
statistically significant differences compared with the control cultures with
vehicle alone are indicated with asterisks (*Po0.05, **Po0.01, and
***Po0.001).
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Figure 3. T-cell-stimulatory capacity of NYT-pretreated DCs. (a, b) BM-DCs
generated from BALB/c mice were incubated for 20 hours with NYT (K) or
vehicle alone (J), washed extensively, and then cocultured at the indicated
numbers with allogeneic T cells (5 104 cells/well) purified from C57BL/6
mice. Data shown are 3H-thymidine uptake on day 4 (mean7SD, n¼ 3).
Statistically significant differences compared with the control cultures with
vehicle alone are indicated with asterisks (*Po0.05 and ***Po0.001).
(a) NYT-treated DCs showed significantly augmented T-cell-stimulatory
activities in four of 10 independent experiments, (b) whereas they were
comparable to vehicle-treated DCs in the other six experiments. (c) To test the
effects of NYT potentially carried over by DCs on responder T cells,
allogeneic T cells were cocultured with NYT- or vehicle-treated DCs (103 or
104 cells/well) in the presence of phorbol myristate acetate plus ionomycin
and examined for their mitogen-induced proliferation on day 2.
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polyene-ergosterol channels (Bolard, 1986). Recent fluores-
cence spectroscopic analyses revealed two phasic inter-
actions of NYT with ergosterol-containing large unilamellar
vesicles; NYT molecules at low concentrations cause
transient structural defects in the lipid membrane, thereby
perturbing its permeability, whereas, upon reaching a critical
threshold, they oligomerize in the lipid membrane to form
transmembrane aqueous channels (Coutinho et al., 2004).
NYT affects not only fungal membranes (rich in ergosterol)
but also mammalian membranes (rich in cholesterol). As a
consequence, NYT inhibits ligand binding to cell surface
receptors by depleting cholesterol from mammalian cell
membranes (Pucadyil et al., 2004) and prevents receptor
recycling and desensitization by blocking caveolae-depen-
dent receptor internalization (Prevostel et al., 2000;
Mueller et al., 2002). Furthermore, NYT has been shown to
prevent CD95-dependent apoptosis of cancer cells (triggered
by agonistic anti-CD95 antibodies or a chemotherapeutic
drug, cisplatin) by interfering with redistribution of CD95
molecules into the lipid rafts (Delmas et al., 2004; Lacour
et al., 2004). Thus, it is conceivable that NYT-dependent
disruption of one or more cell membrane functions may
be sensed by DCs as ‘‘endogenous’’ danger signals, thereby
leading to NFkB activation and a series of maturational
changes.
NYT also appears to exert a DC-stimulatory activity in vivo
because subcutaneous injection of a small amount (2 mg/
animal) of NYT into mice resulted in significant reduction in
surface densities of MHC IIþ epidermal LCs and their
morphological changes (Figure S1). In this regard, amphot-
ericin B, a structural homolog of NYT with an equally potent
antifungal activity, was reported more than 25 years ago to
enhance allergic contact hypersensitivity responses in mice
(Shirley and Little, 1979a, b), although the underlying
mechanisms have remained totally unknown. Conversely,
NYT has been shown to inhibit DC–T-cell interaction during
antigen presentation at high concentrations by disrupting
lipid raft formation (Anderson et al., 2000; Meyer zum
Bueschenfelde et al., 2004). This pharmacological property
may explain our seemingly paradoxical observations that
NYT pretreatment of BM-DCs augmented their T-cell-
stimulatory capacity only marginally and only in some of
the experiments, whereas the same treatment potently
induced phenotypic alteration and cytokine elaboration in a
highly reproducible manner. It is also tempting to speculate
that NYT may facilitate fungal clearance not only through its
direct antifungal activity but also by causing partial activation
of tissue-resident immature DCs. In fact, efficient protection
against Candida albicans requires both innate immunity and
Th1-tailored adaptive immunity (Romani, 1999; Ashman
et al., 2004), and IL-12-producing DCs reportedly play
crucial roles in initiating immune protection against
C. albicans (d’Ostiani et al., 2000; Bacci et al., 2002).
Obviously, further in vivo studies in experimental animals
and human patients are required to assess any clinical
significance of our in vitro findings. Nevertheless, the present
study provides new insights into the pharmacological
mechanisms of action of NYT, a polyene macrolide antibiotic




The XS106-pIL1-YFP DC clone and the parental XS106 DC line were
maintained as described previously (Mizumoto et al., 2005a, b). BM
cells isolated from BALB/c mice (8–12-weeks-old female) were
cultured in the presence of 10 ng/ml GM-CSF and the cells harvested
on day 5 or 6 containing 80–95% CD11cþ cells were used as BM-
DC preparations without further purification (Mizumoto et al.,
2005a). All animal experiments were conducted according to the
National Institutes of Health guidelines and were approved by the
Institutional Review Board. NYT (Prestwick Chemical, Illkirch,
France) was dissolved in DMSO at the concentration of 5 mg/ml
and then diluted with PBS. None of the reagents contained
detectable amounts of endotoxin, as tested by the QCL-1000 system
(Cambrex Bio Science, Walkersville, MD).
Assays to assess DC activation
The XS106-pIL1-YFP DCs were incubated in 96-well plates
(5 104 cells/200 ml/well) for 16 hours with NYT at different con-
centrations or vehicle alone and then examined for YFP expression
and PI uptake using FACSCalibur (BD Biosciences, San Jose, CA)
equipped with an automated high throughput sampler device (BD
Biosciences) (Mizumoto et al., 2005a). The parental XS106 DCs
were incubated for 6 hours with 4 mg/ml NYT or vehicle alone, and
nuclear extracts prepared from these cultures were then measured
for NFkB p50, p65, c-Rel, and RelB subunits using the BD
TransFactor Family Kit (BD Biosciences) (Mizumoto et al., 2005a).
In vitro effects of NYT on BM-DCs
The BM-DC preparations were cultured for 20 hours in 24-well
plates (1 106 cells/ml) in the presence of NYT at different
concentrations or vehicle alone. Cells harvested from these
cultures were examined for surface phenotype and PI uptake
within the CD11cþ DC populations. Supernatants collected from
the same BM-DC cultures were analyzed for cytokines and
chemokines by enzyme-linked immunosorbent assay. In other
experiments, BM-DCs were incubated for 20 hours with NYT (4
or 10mg/ml) or vehicle alone, washed extensively, and then
cocultured with T cells (5 104 cells/well) purified from allogeneic
C57BL/6 mice. The viability of CD11cþ populations in those
allo-mixed leukocyte reaction microcultures was examined on
day 1 by PI uptake, and proliferative responses of T cells were
measured by 3H-thymidine uptake on day 4 (Mizumoto et al.,
2005a). In some experiments, T cells were stimulated with phorbol
myristate acetate (3 nM) plus ionomycin (0.3 mM) in the presence of
NYT- or vehicle-pretreated DCs and examined for 3H-thymidine
uptake on day 2.
Statistical analysis
Comparisons between two groups were performed using a two-tailed
Student’s t-test. The experiments were repeated 2–10 times to assess
the extent of reproducibility of the results.
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SUPPLEMENTARY MATERIAL
Figure S1. In vivo impact of NYT on epidermal LCs. (a) NYT (50 mg/ml, 40 ml/
ear or vehicle alone (40 ml/ear) was injected s.c. into the right or left ears of the
same BALB/c mice, respectively. Epidermal sheets prepared from the ear skin
samples 48 hours after injection were stained for MHC II. The data shown are
the distribution and morphology of MHC IIþ epidermal LCs in representative
field. Bar, 100mm. It should be noted that the ear thickness remained
unchanged by NYT injection at 4 hours (18877 mm, n¼5), 24 hours
(187711 mm), and 48 hours (18375 mm) compared to the control ears
injected with vehicle alone (185711 mm at 4 hours, 18777 mm at 24 hours,
and 18276 mm at 48 hours). (b) The same epidermal sheet preparations were
examined for the number of MHC IIþ LCs. The data shown are the surface
densities of MHC IIþ LCs (mean7SD, 5 mice/panel) in two independent
experiments. Statistically significant differences compared with the control
ears injected with vehicle alone are indicated with asterisks (***Po0.001).
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